Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CRBP
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | MPM BioImpact LLC | 1.67M | 8.6% | SCHEDULE 13G ↗ |
| Nov 2, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Chen Bihua | 1.50M | 7.8% | SCHEDULE 13G/A ↗ |
| Nov 2, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP | 1.50M | 7.8% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | abrdn Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Aberdeen Group plc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Sep 30, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | RA Capital Healthcare Fund, L.P. | 1.91M | 9.9% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Rajeev Shah | 1.91M | 9.9% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Peter Kolchinsky | 1.91M | 9.9% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | RA Capital Management, L.P. | 1.91M | 9.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Kenneth Griffin | 206,354 | 1.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Securities GP LLC | 206,354 | 1.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Securities Group LP | 206,354 | 1.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Securities LLC | 206,354 | 1.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel GP LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Advisors Holdings LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Advisors LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jul 27, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | BlackRock, Inc. | 1.09M | 5.9% | SCHEDULE 13G ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Ting Jia | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Octagon Investments Master Fund LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Octagon Capital Advisors LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Ting Jia | 955,000 | 5.4% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Octagon Investments Master Fund LP | 955,000 | 5.4% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Octagon Capital Advisors LP | 955,000 | 5.4% | SCHEDULE 13G/A ↗ |
| Jan 16, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | abrdn Inc. | 1.32M | 7.5% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Aberdeen Group plc | 1.32M | 7.5% | SCHEDULE 13G ↗ |
| Dec 15, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Chen Bihua | 2.34M | 13.4% | SCHEDULE 13G/A ↗ |
| Dec 15, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP | 2.34M | 13.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Bihua Chen | 2.38M | 12.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP | 2.38M | 12.8% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Kenneth Griffin | 980,610 | 5.3% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Securities GP LLC | 107,297 | 0.6% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Securities Group LP | 107,297 | 0.6% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Securities LLC | 107,297 | 0.6% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel GP LLC | 873,313 | 4.7% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Advisors Holdings LP | 873,313 | 4.7% | SCHEDULE 13G ↗ |
| Nov 12, 2025 | SCHEDULE 13G | CRBP Corbus Pharmaceuticals Holdings, Inc. | Citadel Advisors LLC | 873,313 | 4.7% | SCHEDULE 13G ↗ |
| Jul 29, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | The Vanguard Group | 599,495 | 4.9% | SCHEDULE 13G/A ↗ |
| Jul 16, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | BlackRock, Inc. | 352,409 | 2.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | OrbiMed Capital LLC | 718,200 | 5.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CRBP Corbus Pharmaceuticals Holdings, Inc. | OrbiMed Advisors LLC | 454,087 | 3.7% | SCHEDULE 13G/A ↗ |
40 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 8:35 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances